Well-nourished patients on MHD are less likely to develop folic acid deficiency as hemodialysis per se is not an indication for folic acid supplementation unless the patient is suffering from hyperhomocysteinemia, hyporesponsiveness to erythropoietin therapy, or malnutrition [3,5,30]. This evidence concerns the gene EPO and hyperhomocysteinemia.